Medical Cannabis Is Now Schedule III: What CA Cultivators Do Now

If you hold a California medical cultivation license through the Department of Cannabis Control, a federal tax rule that has quietly shaped your entire business just changed — and almost no one has told you what to do about it. This is written for you: the single-location, state-licensed operator who has watched too much of every year's profit disappear into a tax bill that never felt like it matched reality.

In late April 2026, the Department of Justice and the Drug Enforcement Administration issued an order moving state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. The DEA announced the change in a press release, and it was reported at the time by Reuters and other outlets. I am pointing you to those sources on purpose: the precise regulatory citation is exactly the kind of detail you confirm against the current record before you rely on it, not something to take on faith from a blog post.

The effect that matters to your return is simple to state. Under current law, qualifying medical cannabis activity is no longer inside the reach of Internal Revenue Code Section 280E. For every year your product sat on Schedule I, §280E did one brutal thing: it disallowed all of your ordinary business deductions except cost of goods sold. That is the rule that has forced licensed operators to pay tax on gross profit instead of real income. Moving qualifying medical activity to Schedule III takes it out of that trap.

What moved — and what did not

What the reschedule reaches: FDA-approved marijuana drug products, and marijuana produced and sold under a qualifying state-issued medical license. Those are now treated as Schedule III.

What it does not touch: adult-use (recreational) cannabis, anything sold outside a license, and synthetic THC all remain on Schedule I. For those activities, §280E still applies exactly the way it did last year. Nothing about the reschedule softens it.

It is worth being precise about what this is and is not, because the headlines were not. Rescheduling is not legalization. It does not fix cannabis banking. It does not preempt or change a single line of California law, and it does not touch your state licensing obligations. It is a federal tax event — a narrow, specific one. It changes how one section of the Internal Revenue Code treats one category of licensed activity, and that is all. Everything else about running a compliant California cannabis business is exactly as hard as it was in March.

What this means for a California medical cultivator

For the first time since you opened your doors, the ordinary and necessary expenses attributable to your medical activity can be deducted on your federal return instead of disallowed. Rent. Payroll for staff who sit outside the production line. Utilities that are not part of cultivation. Marketing. Professional fees. For a profitable single-location cultivator, that is the whole difference between being taxed on gross profit and being taxed on what you actually earned — and it is not a rounding error.

One clarification first, because I get this question every week: cost of goods sold was never the part §280E took away. Even under Schedule I, a cultivator could always subtract the direct costs of producing the plant — that is what kept the tax from being outright confiscatory. What §280E disallowed was everything below that line, the general and administrative overhead any normal business writes off as a matter of course. So the win here is specific. It is not that your product suddenly became cheaper to grow; it is that the overhead you were already spending finally counts against your income on the medical side of the house.

Put a number on it in your own head. Take the overhead §280E has been disallowing every year, multiply it by your effective federal rate, and that is roughly what the old regime cost you annually for nothing. The reschedule does not send you a check, but for the medical portion of your business it can stop the bleeding going forward. What it is worth to you depends entirely on your numbers — which is why the honest answer to "how much" starts with looking at your books, not at a headline.

There is a new compliance wrinkle to sit with, too. A Schedule III substance lives inside a different federal registration framework than a Schedule I one, and state-licensed medical operators may now carry registration obligations they simply did not have before. I am not going to tell you from a web page what your specific obligation is or is not — confirm the details, and any deadlines that come with them, with your counsel or a qualified advisor. It is on the checklist below for exactly that reason.

And here is the catch that is also the opportunity. Most of the cultivators I work with are not purely medical. If you hold both a medical and an adult-use designation, you now run two activities with two different federal tax treatments under one roof — the medical side outside §280E, the adult-use side still squarely inside it. That means every shared cost has to be split between them: the rent on a building that grows both, the salary of a manager who runs both, the power bill for a room that serves both. Allocation is where this stops being theory and starts being money. I walk through the mechanics in the next guide in this library, The Medical-vs-Adult-Use Allocation.

Five things to do now

1. Confirm your license designation actually qualifies. The federal treatment turns on medical activity under a qualifying state license. Confirm your DCC license carries the medical ("A") designation the reschedule depends on — not only an adult-use designation. If you hold adult-use alone, none of this changes your §280E position.
2. Confirm any new DEA registration requirements — and their deadlines — with counsel. Do not assume, and do not reverse-engineer your obligation from a forum thread. Get it from someone who can put it in writing and stand behind it.
3. Start segregating your books now, medical versus adult-use — across revenue, cost of goods sold, and overhead. If you cannot show the split cleanly, you cannot defend the allocation, and the allocation is the whole game this year.
4. Pull your prior-year return and the allocation method it used. Flag whether a corrected allocation — or an amended return — is in play. That is its own decision, with its own risks and deadlines, and I cover it in a companion guide on amended returns and refund claims.
5. Do not file 2026 on the old, all-§280E assumption. Get the allocation reviewed before the return goes out. The timing and transition-year treatment for 2026 specifically is precisely the kind of thing to verify against current IRS guidance before you file — not to assume from a headline, and not to guess.

The expensive mistake

The costly error this year is filing 2026 with no allocation, or a careless one. Do that and you land in one of two bad places. Either you overpay — leaving real money with the IRS on a §280E assumption that may no longer apply to your medical activity — or you take an aggressive position the IRS later disallows, and now you are looking at an examination, back tax, and penalties on top of it. Neither is where you want to be, and both are avoidable.

There is one more reason to document everything and keep your positions defensible: the rescheduling order is itself under legal challenge. That does not make it wrong to rely on current law — it makes it essential that any position you take is one you can support on the record, in case the ground shifts again. I cover the litigation risk and what it means for how you file in a separate guide in this library. Build the file now, while the facts are fresh and the paperwork is in front of you.